港股生物科技板块近日再现异动：创新药企和铂医药（2142.HK）以连续五日回购的强势姿态引发市场关注。 港交所最新数据显示，5月12日公司斥资976.03万港元回购120万股，将月内累计回购金额推升至2968.6万港元，当月共计358.8万股 筹码被收入囊中。 这一系列资本运作背后，公司股价早已走出惊人曲线——截至5月12日收盘，年内累计最大涨幅突破400%大关，总市值攀升至69亿 港元。 在生物医药行业普遍面临资本寒冬的背景下，和铂医药的逆势表现尤为抢眼。据2024年财报显示，这家实现连续两年盈利的创新药 企，全年经常性收入首破亿元关口，账上现金储备达12亿元人民币。 当多数Biotech仍在研发投入与商业化变现间艰难平衡时，和铂医药选择大举回购，管理层持续将千万级资金注入自家股票，这究竟 释放着怎样的市场信号？ 7000万港元回购背后的"信心升级" 当外部市场风起云谲之际，和铂医药正在用真金白银的资本语言书写新篇章。 根据WIND数据显示，2025年开年仅五个月，公司已斥资7018.8万港元回购1407.8万股，其中5月以来更是连续五日持续回购，累计 回购金额2968.6万港元。 这一连串密集操作，恰似管 ...

和铂医药-B回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.05.12 | 120.00 | 8.580 | 7.960 | 976.04 | | 2025.05.09 | 18.80 | 8.700 | 8.450 | 161.13 | | 2025.05.08 | 50.00 | 8.390 | 8.190 | 418.15 | | 2025.05.07 | 130.00 | 8.620 | 8.030 | 1067.48 | | 2025.05.06 | 40.00 | 8.790 | 8.530 | 345.81 | | 2025.04.30 | 27.00 | 8.590 | 8.540 | 231.56 | | 2025.04.23 | 40.00 | 7.920 | 7.840 | 315.90 | | 2025.04.17 | 28.90 | 7.350 | 7.180 | 209.13 | | 2025.04.16 | 75.00 | 7.350 ...

和鉑醫藥控股有限公司 年度報告 2024 HBM HOLDINGS LIMITED ANNUAL REPORT 2024 年報 目錄 | 公司資料 | 2 | 獨立核數師報告 | 98 | | --- | --- | --- | --- | | 財務摘要 | 4 | 綜合損益表 | 103 | | 業務摘要 | 5 | 綜合全面收益表 | 104 | | 主席致辭 | 9 | 綜合財務狀況表 | 105 | | 管理層討論與分析 | 13 | 綜合權益變動表 | 107 | | 董事及高級管理層 | 35 | 綜合現金流量表 | 109 | | 董事會報告 | 40 | 綜合財務報表附註 | 112 | | 企業管治報告 | 76 | 釋義 | 202 | | 風險管理報告 | 96 | | | 和鉑醫藥控股有限公司 年報2024 和鉑醫藥控股有限公司 年報2024 公司資料 董事會 執行董事 獨立非執行董事 Robert Irwin Kamen博士 葉小平博士 邱家賜先生 （自二零二四年六月二十一日起辭任） Albert R. Collinson博士 陳維維女士 （自二零二五年一月一日起獲調任） 審核委員會 ...

广发证券认为，当前资本市场的关注焦点正悄然从传统的地产和政策周期转向更具长期战略意义的中美 科技博弈。该行建议重视港股创新药的配置价值，原因在于：核心逻辑一：中国创新药出海的全球竞争 优势正在凸显；核心逻辑二：当前关税政策对创新药影响远小于其他成长性板块；核心逻辑三：政策及 监管态度逐步转向对板块有利的情形。2023年下半年以来，政策层面出现了一系列积极信号，标志着行 业监管思路的调整，包括但不限于集采规则优化、创新药支持政策加码、医疗反腐常态化与纠偏。 此外，财报层面：头部港股创新药公司受益于License-out放量，营收和利润稳步增长。估值层面：年初 以来科技股的放量大涨之后，医药板块相比于其他成长行业，估值处于相对安全的区间。该行表示，年 初以来在DeepSeek的激励下，港股市场交投情形改善显著，相比之下，港股医药板块的关注度并不算 高，对医药的基本面修复，市场定价或尚不充分。 智通财经APP获悉，医药股早盘涨幅居前，截至发稿，再鼎医药(09688)涨14.86%，报25.5港元；和铂医 药-B(02142)涨10.07%，报7.87港元；荣昌生物(09995)涨8.22%，报30.95港元；君实生 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 截至二零二四年十二月三十一日止年度的 年度業績公告 和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）欣然公佈本集團截至二零二四年十二月三十一日止年度（「報 告期」）的經審核綜合年度業績。該等年度業績已由本公司的審核委員會（「審核委 員會」）審閱。 於本公告內，「我們」指本公司，惟倘文義另有所指，則指本集團。 財務摘要 | | 於十二月三十一日╱ | | | --- | --- | --- | | | 截至十二月三十一日止年度 | | | | 二零二四年 | 二零二三年 | | | 千美元 | 千美元 | | 收入 | 38,100 | 89,502 | | 銷售成本 | (4,486) | (2,034) | | 其他收入及收益 | ...

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of 12.07 HKD based on a current price of 5.2 HKD [6]. Core Insights - The company, Heptagon Pharmaceuticals, established in 2016, focuses on innovative drug development and commercialization in the fields of immunology and oncology. It has shown significant revenue growth from 0.1 million RMB in 2018 to 634 million RMB in 2023, achieving profitability in 2023 [1][14]. - The proprietary Harbour Mice® antibody platform is highlighted as a unique asset, enabling the production of both conventional and heavy-chain human monoclonal antibodies, which positions the company as a leader in antibody innovation [2][25]. - The company has over 10 drug candidates in various stages of clinical development, with key products like Batoclimab (HBM9161) and HBM9378 showing promising progress [3][38]. Summary by Sections 1. Company Overview - Heptagon Pharmaceuticals specializes in the development of innovative drugs in immunology and oncology, leveraging a unique business model that combines self-research and collaboration [1][12]. - The company has transitioned from significant losses in previous years to profitability in 2023, with a net profit of 161 million RMB [14][17]. 2. Antibody Development Platform - The Harbour Mice® platform allows for the generation of both H2L2 and HCAb formats of human monoclonal antibodies, showcasing its broad application potential [2][25]. - The HCAb platform is noted for its ability to produce various forms of antibodies, including mRNA and bispecific antibodies, which enhances the company's development capabilities [2][31]. 3. Clinical Pipeline - The company has a robust pipeline with over 10 candidates focused on autoimmune and oncology diseases, with Batoclimab (HBM9161) and HBM9378 being the most advanced [3][38]. - Batoclimab has received acceptance for its BLA by NMPA, indicating its potential as a significant therapy for autoimmune diseases [41]. 4. Business Development - Heptagon has established numerous partnerships with leading pharmaceutical companies, enhancing its business development efforts and expanding its collaborative reach [4][40]. - The company has signed multiple licensing agreements, contributing to its revenue growth and positioning it favorably within the industry [17][40]. 5. Financial Projections - The report forecasts total revenues of 260 million RMB, 417 million RMB, and 566 million RMB for 2024, 2025, and 2026 respectively, based on the performance of key products [5][10].

Financial Performance - Revenue for the six months ended June 30, 2024, was $23.7 million, a decrease of 42.2% compared to $41.0 million for the same period in 2023[3]. - The company reported a net profit of $1.4 million for the first half of 2024, compared to a profit of $2.9 million in the same period of 2023, representing a decline of 52.1%[3]. - Gross profit for the period was $22.516 million, down from $40.973 million, reflecting a significant decline in sales[86]. - The company reported a profit before tax of $1.724 million, compared to $2.903 million in the previous year, showing a decline of 40.5%[86]. - Total comprehensive income for the period was $1.708 million, a decrease of 65.8% from $4.999 million in the same period of 2023[87]. - Profit for the reporting period decreased from $2.9 million for the half-year ended June 30, 2023, to $1.4 million for the same period in 2024, a decline of 48.3%[47]. Research and Development - Research and development expenses amounted to $13.1 million, down from $28.4 million in the previous year, reflecting a reduction of 53.8%[3]. - Employee costs in R&D dropped from $8.8 million to $6.6 million, contributing to the overall reduction in R&D expenses[43]. - The company reported R&D costs of $13.1 million for the six months ended June 30, 2024, down from $28.4 million for the same period in 2023, reflecting a decrease of 53.8%[39]. - The company has over 10 candidate drugs focused on tumor and immune diseases, ranging from preclinical to late-stage clinical phases[16]. - The company aims to expand its platform applications into immunology and inflammation fields, leveraging its Harbour Mice® and HBICE® discovery engines to identify new high-quality candidate molecules[38]. Cash and Assets - Cash and cash equivalents increased to $183.0 million as of June 30, 2024, up from $140.3 million at the end of 2023, indicating a growth of 30.4%[4]. - Total assets decreased to $219.7 million from $228.5 million, a decline of 3.0%[4]. - The company’s total liabilities reduced to $96.9 million, down 11.0% from $108.9 million[4]. - Current assets amounted to $202,891,000, down from $210,176,000, indicating a decrease of about 3.9%[88]. - Total liabilities decreased to $58,736,000 from $64,130,000, a reduction of about 8.3%[88]. Licensing and Collaborations - The company entered into a global licensing agreement with Seagen Inc. for HBM9033, with an upfront payment of $19 million expected upon deal completion[10]. - Harbour Therapeutics' BLA for HBM9161 for treating gMG was accepted by NMPA in July 2024[6]. - The collaboration with AstraZeneca includes an upfront payment of $19 million and potential milestone payments totaling up to $575 million[32]. - The company is actively exploring drug development strategies and seeking collaboration opportunities for its pipeline products[26][27][28][29][30]. Shareholder Information - As of June 30, 2024, the total number of issued shares is 768,876,410[70]. - Major shareholder Yongfengli Investment Limited owns 93,561,360 shares, which is about 12.17% of the total equity[72]. - The shareholding structure indicates significant control by a few major shareholders, with concentrated ownership among investment entities[73]. - The company has granted Dr. Wang 7,200,000 options and 956,500 restricted shares under post-IPO plans[74]. Corporate Governance - The audit committee includes two independent non-executive directors and one non-executive director, with a focus on reviewing financial statements and internal controls[63]. - The company has established a compensation committee as part of its governance structure[164]. - The company is subject to regulations by the National Medical Products Administration (NMPA) in China[165]. - The company is also regulated by the U.S. Food and Drug Administration (FDA)[165]. Future Outlook - The company aims to maximize platform value through a flexible business model leveraging complementary advantages with partners[14]. - The company plans to focus on the development of products from its proprietary platform and explore the expansion of its collaboration network[38]. - The company aims to submit at least one IND application annually generated from its discovery engine[25].

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of $23.701 million, a decrease from $40.996 million in the same period of 2023, representing a decline of approximately 42.2%[2] - The company recorded a net profit of $1,397,000 for the six months ended June 30, 2024, compared to $2,914,000 in the same period of 2023, representing a decline of 52.1%[60] - Gross profit for the same period was $22,516,000, down from $40,973,000, reflecting a significant decline in profitability[59] - Revenue from major clients contributing over 10% to total revenue was $19,133 thousand in 2024, down from $39,837 thousand in 2023[72] - Revenue from product licensing fees was $20,832 thousand, while research service fees contributed $2,326 thousand in the first half of 2024[73] - The company reported a pre-tax loss of $874 thousand in the first half of 2024, compared to a profit of $23 thousand in the same period of 2023[78] - The company incurred a total tax expense of $(327) thousand in the first half of 2024, compared to $11 thousand in the same period of 2023[84] - The company has not declared or paid any dividends during the reporting period[85] Assets and Liabilities - The total assets as of June 30, 2024, were $183.038 million, compared to $140.324 million as of December 31, 2023, indicating an increase of about 30.4%[2] - The total liabilities decreased to $96.899 million from $108.851 million, reflecting a reduction of approximately 11%[2] - The company’s total equity increased to $122,807,000 as of June 30, 2024, compared to $119,629,000 at the end of 2023, indicating a positive trend in shareholder equity[64] - The total bank loans amount to $65.0 million, with lease liabilities of $1.2 million as of June 30, 2024[47] - Trade receivables as of June 30, 2024, amounted to $1.471 million, a significant decrease from $52.323 million as of December 31, 2023[89] - Trade payables as of June 30, 2024, totaled $5.382 million, down from $15.363 million at the end of 2023[90] Research and Development - The company has over 10 drug candidates focused on oncology and immune-related diseases, ranging from preclinical to late-stage clinical development[9] - The company aims to address unmet medical needs in oncology and immune diseases through innovative antibody therapies[5] - HBM4003, a next-generation fully human anti-CTLA-4 antibody, has shown positive efficacy and safety data in clinical trials for various solid tumors[13] - The company initiated a Phase I clinical trial for HBM9027 in January 2024, following the approval of an Investigational New Drug (IND) application by the FDA[3] - HBM1022, targeting CCR8, has received IND approval in the U.S. and is aimed at treating solid tumors globally[10] - The company is preparing for a Phase 2 trial for HBM9378, targeting asthma and chronic obstructive pulmonary disease[10] - HBM7020, targeting BCMAxCD3, has received IND approval in China for treating hematological malignancies[10] - HBM9378, targeting TSLP, completed its Phase I clinical trial in October 2023, with plans for a Phase II trial for severe asthma and an IND application for COPD[17] - The company aims to submit at least one IND application annually from its discovery engine, focusing on differentiated antibody therapies in oncology and immunology[19] Collaborations and Agreements - A global licensing agreement was signed with AstraZeneca in May 2024, which includes an upfront payment of $19 million and potential milestone payments totaling up to $575 million[4] - The collaboration with CSPC Pharmaceutical Group for HBM9161 is expected to optimize market potential and advance clinical development[12] - The company established partnerships with over 25 industry pioneers and academic institutions to expand its global collaboration network[25] - The company is exploring additional platform-based collaborations to enhance its product pipeline and market presence[4] - In February 2023, the company entered into a licensing and collaboration agreement with Cullinan Therapeutics for HBM7008, which will be terminated in November 2024, allowing the company to regain global rights[14] Cost Management and Expenses - R&D costs significantly decreased from $28.4 million for the six months ended June 30, 2023, to $13.1 million for the same period in 2024, a reduction of 53.8%[37] - Administrative expenses decreased to $7.9 million for the six months ended June 30, 2024, from $8.6 million for the same period in 2023, reflecting improved cost management[39] - Employee costs for R&D represented 50.2% of total R&D expenses for the six months ended June 30, 2024, compared to 31.2% for the same period in 2023[38] - The total employee compensation cost for the first half of 2024 is $13.2 million, compared to $14.4 million for the same period in 2023[48] Future Outlook - The company plans to focus on the development of products from its proprietary platform and explore expansion of its collaboration network[32] - The company expressed confidence in its ability to provide innovative treatments for immune diseases and cancer patients in the near future[31] - The company is incubating several joint ventures focused on developing next-generation therapies, utilizing a "technology for equity" model to minimize investment[29]

• 開發基於新型全人源僅重鏈抗體的mRNA編碼T細胞銜接器，用於腫瘤免疫治療，其在mRNA 療法峰會(mRNA Therapy Summit)上以海報形式展示。 和鉑醫藥控股有限公司 32 年報2023 截至二零二三年十二月三十一日，該投資公允價值為5.75百萬美元，佔本公司總資產的2.52%。於報 告期內，本集團就其於恩凱賽藥的投資錄得未實現公允價值變動虧損0.51百萬美元。 自成立以來，我們致力於為全球患者研發創新療法，成為具有核心技術優勢和差異化產品管線的創 新生物製藥公司。二零二四年Harbour Therapeutics將進一步加速推進產品管線。我們將繼續投資於 HBM4003、HBM1020以及其他由我們的發現平台產生的，並採用針對新靶點的分子項目或針對已知 靶點的創新分子項目。此外，我們預計將有至少兩個新產品申報IND，通過Harbour Mice®和HBICE® 這兩個高效藥物發現引擎，我們將持續地發現新的優質候選分子。 我們將重新分配內部資源，專注於來源於我們自主平台產品的開發，以及諾納生物合作網絡的擴展。 收入 本集團並無詳細的重大投資或資本資產的未來計劃。 於二零二三年十二月三十一日，本 ...

Product Development and Clinical Trials - HBM9027 received IND approval from the FDA in January 2024, initiating Phase I trials in the US[5] - HBM7004, a novel B7H4xCD3 bispecific antibody, is designed to provide new solutions for tumor immunotherapy, enhancing both efficacy and safety[5] - HBM1047 demonstrated significant antitumor efficacy in various preclinical models, with a maximum tolerated dose of 200 mg/kg in primate studies[12] - The company completed a Phase III clinical trial for HBM9161 in March 2023, indicating progress in its product development pipeline[172] - The company announced the completion of Phase I clinical trials for HBM9378 in October 2023, targeting neuroendocrine tumors/cancers (NET/NEC)[174] - HBM1022 received IND approval from the FDA in February 2023 to initiate Phase I trials for solid tumors[176] - HBM1007 received IND approval from the FDA in January 2023 to start Phase I trials for solid tumors[182] - The company reported the completion of patient recruitment for Phase I trials in March 2023[180] - Bartolizumab (HBM9161) completed patient treatment in early 2023, with positive Phase III trial results for gMG announced in March 2023, marking a significant milestone as the company's first Phase III trial ready for commercialization[200] - The open-label extension clinical trial for Bartolizumab was initiated in 2022 and completed enrollment in March 2023, with ongoing analysis showing sustainable efficacy and safety for long-term disease management as of November 2023[200] - Bartolizumab's Biologics License Application (BLA) was accepted by NMPA in June 2023, representing the first BLA accepted since the company's establishment[200] - The company plans to voluntarily include additional long-term safety data and resubmit the BLA for Bartolizumab in December 2023[200] Financial Performance - For the fiscal year ending December 31, 2023, the company reported revenue of $89.5 million, a significant increase of $48.8 million or 119.9% compared to $40.7 million for the fiscal year ending December 31, 2022[40] - The company achieved a profit of $22.8 million for the fiscal year ending December 31, 2023, a substantial turnaround from a loss of $137.3 million in the previous year, an increase of $160.1 million[56] - The company reported a net profit of $22,797 million for 2023, recovering from a loss of $137,222 million in 2022[120] - Basic earnings per share for 2023 were $0.03, compared to a loss of $0.19 per share in 2022[120] - The gross profit for the year was $87,468 thousand, significantly up from $40,529 thousand, indicating a strong improvement in profitability[81] - The increase in revenue was primarily driven by licensing agreements with Seagen, Cullinan, and Keren Bio[41] - The company reported a total of $10,942,000 in software and technology licensing costs as of December 31, 2023, compared to $10,900,000 in 2022, showing a slight increase[135] - Other income and gains increased from $4.8 million for the fiscal year ending December 31, 2022, to $6.6 million for the fiscal year ending December 31, 2023, primarily due to increased interest income from higher cash balances[43] Research and Development - Research and development expenses decreased to $45.1 million for the fiscal year ending December 31, 2023, down from $135.1 million in the previous year, representing a reduction of $90.0 million or 66.6%[52] - The company utilized $405.4 million for the clinical trials and related R&D activities of its core product HBM9161, with no remaining unutilized funds as of December 31, 2023[79] - The company has a strategic focus on developing differentiated products with clear clinical value to meet unmet clinical needs, particularly in the Greater China market[195] - The company’s proprietary antibody technology platform, Harbour Mice®, enables the generation of fully human monoclonal antibodies, enhancing its innovation and sustainable growth[192] - The company is actively pursuing the commercialization of its core products, including HBM9161 and HBM9036, with ongoing clinical trials in the Greater China region[78] Collaborations and Licensing Agreements - In April 2022, the company entered a global licensing agreement with AstraZeneca for HBM7022, which has received IND approvals from the FDA and NMPA in 2023[13] - The company secured a $25 million upfront payment and potential milestone payments of up to $600 million from Cullinan for HBM7008[13] - A licensing agreement with Pfizer for HBM9033 was signed in December 2023, providing $53 million in upfront payments and up to $1.05 billion in milestone payments[19] - The company is expanding its collaboration network globally, partnering with industry leaders and academic researchers to maximize the value of its proprietary technology platform[18] - The company announced a strategic collaboration with INGENIA Therapeutics in October 2023 to accelerate the development of innovative therapies for immune diseases[178] - The company is advancing a partnership with Boston Children's Hospital to develop new antibody therapies using its target discovery and antibody design platform[187] Corporate Governance and Compliance - The company has established an audit committee, nomination committee, and remuneration committee to enhance corporate governance[75] - The company plans to adopt revised international financial reporting standards when they become effective[96] - The company is committed to addressing the challenges posed by new regulatory requirements in clinical trials and patient privacy protection globally[197] Market Position and Strategy - The company aims to optimize its strategies in research, development, registration, and global collaboration to enhance its market position[197] - The company anticipates regulatory approvals for multiple products in the U.S. market in early 2024, indicating a proactive approach to market entry[194] - The Chinese pharmaceutical industry is undergoing significant reforms, impacting drug pricing and market dynamics, which the company is strategically navigating[195] - The company’s focus on innovative drug development aligns with the growing demand driven by healthcare upgrades and an aging population[197]